Literature DB >> 19041826

Surgical approaches in thyroid cancer and lymph-node metastases.

Henning Dralle1, Andreas Machens.   

Abstract

Thyroid cancer collectively encompasses a variety of tumors of disparate morphology and biology. With the exception of radio-iodine therapy for iodine-concentrating well-differentiated thyroid cancers, surgery is the foremost and generally sole effective treatment. Because the growth patterns of these tumors vary tremendously, there is a need to tailor the extent of dissection to the respective tumor entity, especially for less aggressive tumors. No international consensus exists about what precisely constitutes a 'low-risk' or 'high-risk' tumor. Established indications for less-than-total thyroidectomy include small (<or=1 cm), unifocal, and non-metastatic papillary thyroid carcinomas (PTC), and minimally invasive follicular thyroid carcinomas (FTC; invasion of the tumor capsule only). Whether occult multifocal PTC and minimally invasive FTC with histopathological evidence of vascular invasion also fall into the 'low-risk' category remains unclear. For node-positive thyroid cancers, compartment-oriented microdissection is the gold standard of care, whereas the concept of prophylactic lymph-node dissection continues to arouse controversy. Most experts agree that routine lymph-node dissection is unnecessary for low-risk well-differentiated thyroid cancer (DTC). Because occult lymph-node metastases are frequent in high-risk PTC and medullary thyroid carcinoma, compartment-oriented microdissection helps prevent reoperations for 'recurrences' arising from residual nodes, sparing patients the excess morbidity from reoperations in the neck. Because of the looming epidemic of early forms of thyroid cancer, an international consensus is needed regarding (1) the definition of low- versus high-risk tumors; (2) classification of neck nodes; and (3) lymph-node dissection terminology.

Entities:  

Mesh:

Year:  2008        PMID: 19041826     DOI: 10.1016/j.beem.2008.09.018

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  15 in total

Review 1.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

2.  [Total thyroidectomy with lymph node dissection of the central compartment for node-positive, capsular invasive papillary thyroid cancer: video contribution].

Authors:  H Dralle; P Nguyen Thanh
Journal:  Chirurg       Date:  2014-10       Impact factor: 0.955

3.  Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer.

Authors:  Jingdong Zhang; Anthony Gill; Bryn Atmore; Amber Johns; Leigh Delbridge; Raymond Lai; Todd McMullen
Journal:  Int J Clin Exp Pathol       Date:  2011-04-28

4.  Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.

Authors:  Michael Stamatakos; Panoraia Paraskeva; Charikleia Stefanaki; Paraskevas Katsaronis; Andreas Lazaris; Konstantinos Safioleas; Konstantinos Kontzoglou
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

5.  SPECT/CT sentinel lymph node identification in papillary thyroid cancer: lymphatic staging and surgical management improvement.

Authors:  Amparo Garcia-Burillo; Isabel Roca Bielsa; Oscar Gonzalez; Carles Zafon; Monica Sabate; Josep Castellvi; Xavier Serres; Carmela Iglesias; Ramon Vilallonga; Enric Caubet; Jose Manuel Fort; Jordi Mesa; Manuel Armengol; Joan Castell-Conesa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-02       Impact factor: 9.236

6.  Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer.

Authors:  L I Yan; L I Li; Qinghuai Li; Wang DI; Wei Shen; Linlei Zhang; Hao Guo
Journal:  Exp Ther Med       Date:  2015-04-07       Impact factor: 2.447

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

8.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

9.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

10.  Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.

Authors:  Atakan Sezer; Mehmet Celik; Buket Yilmaz Bulbul; Nuray Can; Ebru Tastekin; Semra Ayturk; Funda Ustun; Sibel Guldiken; Necdet Sut
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.